177 related articles for article (PubMed ID: 31087496)
1. Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.
Wang Z; Dai J; Yan J; Zhang Y; Yin Z
J Cell Mol Med; 2019 Jul; 23(7):4770-4778. PubMed ID: 31087496
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
3. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
5. MiR-600 mediates EZH2/RUNX3 signal axis to modulate breast cancer cell viability and sorafenib sensitivity.
Zhao Q; Li D; Feng J; Jinsihan D
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23613. PubMed ID: 38229326
[TBL] [Abstract][Full Text] [Related]
6. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2.
Esposito F; Tornincasa M; Pallante P; Federico A; Borbone E; Pierantoni GM; Fusco A
J Clin Endocrinol Metab; 2012 May; 97(5):E710-8. PubMed ID: 22399519
[TBL] [Abstract][Full Text] [Related]
8. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
[TBL] [Abstract][Full Text] [Related]
9. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of microRNA-218 via EZH2-mediated H3K27 trimethylation is involved in malignant transformation of HBE cells induced by cigarette smoke extract.
Wang B; Liu Y; Luo F; Xu Y; Qin Y; Lu X; Xu W; Shi L; Liu Q; Xiang Q
Arch Toxicol; 2016 Feb; 90(2):449-61. PubMed ID: 25526925
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
[TBL] [Abstract][Full Text] [Related]
12. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y; Chiba T; Oshima M; Koide S; Rizq O; Aoyama K; Ao J; Kaneko T; Kanzaki H; Kanayama K; Maeda T; Saito T; Nakagawa R; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Nakamoto S; Yasui S; Mikata R; Muroyama R; Kanda T; Maruyama H; Kato J; Mimura N; Ma A; Jin J; Zen Y; Otsuka M; Kaneda A; Iwama A; Kato N
Sci Rep; 2021 Nov; 11(1):21396. PubMed ID: 34725436
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
14. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness.
Tseng CF; Chen LT; Wang HD; Liu YH; Shiah SG
Cancer Sci; 2022 May; 113(5):1601-1612. PubMed ID: 35253323
[TBL] [Abstract][Full Text] [Related]
16. A sorafenib-sparing effect in the treatment of thyroid carcinoma cells attained by co-treatment with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3.
Izkhakov E; Sharon O; Knoll E; Aizic A; Fliss DM; Kohen F; Stern N; Somjen D
J Steroid Biochem Mol Biol; 2018 Sep; 182():81-86. PubMed ID: 29702263
[TBL] [Abstract][Full Text] [Related]
17. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
18. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
[TBL] [Abstract][Full Text] [Related]
19. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
Yang F; Lv LZ; Cai QC; Jiang Y
World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
[TBL] [Abstract][Full Text] [Related]
20. miR-98 inhibits hepatocellular carcinoma cell proliferation via targeting EZH2 and suppressing Wnt/β-catenin signaling pathway.
Zhang JJ; Chen JT; Hua L; Yao KH; Wang CY
Biomed Pharmacother; 2017 Jan; 85():472-478. PubMed ID: 27890434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
